Advertisement

Topics

EC Approves Olaparib for BRCA Breast Cancer

11:33 EDT 16 Apr 2019 | Medscape

The European Commission has cleared olaparib (Lynparza, AstraZeneca/MSD) for the treatment of locally advanced or metastatic BRCA1/2 breast cancer.
International Approvals

Original Article: EC Approves Olaparib for BRCA Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "EC Approves Olaparib for BRCA Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...